Novo Nordisk AS (OCSE:NOVO B)
kr 775.8 18.5 (2.44%) Market Cap: 3.45 Til Enterprise Value: 3.43 Til PE Ratio: 36.59 PB Ratio: 28.65 GF Score: 97/100

Q4 2019 Novo Nordisk A/S Earnings Call Transcript

Feb 05, 2020 / 12:00PM GMT
Release Date Price: kr217.5 (+4.58%)
Operator

Hello, and welcome to the Q4 2019 Novo Nordisk A/S Earnings Conference Call. (Operator Instructions)

Today, I'm pleased to present Lars Fruergaard Jørgensen, CEO. Please go ahead with your meeting.

Lars Fruergaard JÃ;rgensen;S;President
Novo Nordisk A;CEO & Member of Management Board

¸ - /- -

Thank you. Welcome to this Novo Nordisk conference call regarding our performance in 2019 and our financial outlook for 2020. I'm Lars Fruergaard Jørgensen, the CEO of Novo Nordisk. With me, I have our Chief Financial Officer, Karsten Knudsen; and our Chief Science Officer, Mads Krogsgaard Thomsen. Also present and available for Q&A sessions are Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest; and Executive Vice President and Head of International Operations, Mike Doustdar; as well as our Investor Relations officers.

Today's earnings release will be -- and the slides for this call will be available on our website, novonordisk.com. The call is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot